Consumption and market share of cholesterol-lowering drugs in high-risk patients before and after the release of the 2013 ACC/AHA cholesterol guidelines: a retrospective observational study.
Tzu-Tsen KuoYaw-Bin HuangChing-Jung HsiehPublished in: BMJ open (2020)
The 2013 ACC/AHA cholesterol guidelines likely promoted the use of fixed-dose, high-intensity and moderate-intensity monotherapy and FDC therapy statins in high-risk groups, and this was consistent with the use of high-intensity or moderate-intensity statins in the present study. Furthermore, these changes were associated with increased effectiveness and reduced adverse effects.
Keyphrases
- high intensity
- resistance training
- low density lipoprotein
- end stage renal disease
- cardiovascular disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical practice
- randomized controlled trial
- peritoneal dialysis
- systematic review
- prognostic factors
- clinical trial
- stem cells
- type diabetes
- combination therapy
- patient reported outcomes
- double blind